Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety

Hironao Okubo, Teppei Matsui, Makoto Chuma, Akihiro Funaoka, Haruki Uojima, Satoshi Narahara, Masahiro Kobayashi, Yuwa Ando, Tsunamasa Watanabe, Taito Fukushima, Satoshi Kobayashi, Katsuharu Hirano, Kota Tsuruya, Tatehiro Kagawa, Shuichiro Iwasaki, Hisashi Hidaka, Hidenari Nagai, Yasuhito Tanaka, Shin Maeda, Manabu Morimoto

Open source

DOI: 10.3390/cancers18162703
Published: 2026-08-20
Container: Cancers
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers18162703,
  title = {Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety},
  author = {Hironao Okubo and Teppei Matsui and Makoto Chuma and Akihiro Funaoka and Haruki Uojima and Satoshi Narahara and Masahiro Kobayashi and Yuwa Ando and Tsunamasa Watanabe and Taito Fukushima and Satoshi Kobayashi and Katsuharu Hirano and Kota Tsuruya and Tatehiro Kagawa and Shuichiro Iwasaki and Hisashi Hidaka and Hidenari Nagai and Yasuhito Tanaka and Shin Maeda and Manabu Morimoto},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18162703},
  url = {https://doi.org/10.3390/cancers18162703}
}

RIS

TY  - JOUR
TI  - Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety
AU  - Hironao Okubo
AU  - Teppei Matsui
AU  - Makoto Chuma
AU  - Akihiro Funaoka
AU  - Haruki Uojima
AU  - Satoshi Narahara
AU  - Masahiro Kobayashi
AU  - Yuwa Ando
AU  - Tsunamasa Watanabe
AU  - Taito Fukushima
AU  - Satoshi Kobayashi
AU  - Katsuharu Hirano
AU  - Kota Tsuruya
AU  - Tatehiro Kagawa
AU  - Shuichiro Iwasaki
AU  - Hisashi Hidaka
AU  - Hidenari Nagai
AU  - Yasuhito Tanaka
AU  - Shin Maeda
AU  - Manabu Morimoto
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18162703
UR  - https://doi.org/10.3390/cancers18162703
ER  -

APA

Okubo, H., Matsui, T., Chuma, M., Funaoka, A., Uojima, H., Narahara, S., Kobayashi, M., Ando, Y., Watanabe, T., Fukushima, T., Kobayashi, S., Hirano, K., Tsuruya, K., Kagawa, T., Iwasaki, S., Hidaka, H., Nagai, H., Tanaka, Y., Maeda, S., & Morimoto, M. (2026). Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety. Cancers. https://doi.org/10.3390/cancers18162703

Source records

crossref · retrieved 2026-09-25T10:27:03.603Z